SEC Form 4 · accession 0001209191-15-051296
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geraldine Henwood
Officer — President and CEO
Period of report
Jun 5, 2015
Accepted (ET)
Jun 9, 2015 · 12:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Jun 5, 2015 | P | 3,950 | $8.83 | A | 103,950 | D | |
| Common StockF2,F3 | Jun 8, 2015 | P | 550 | $9.56 | A | 104,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.39 to $9.09, inclusive.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.52 to $9.59, inclusive.
- F3The reporting person undertakes to provide to Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.